US Edition'Transformational' new drug could stop breast cancer tumours before they grow, trial finds
- Researchers presented results from the Serena-6 trial in 2025, showing that camizestrant delays breast cancer progression worldwide.
- The trial targeted patients with hormone receptor-positive, HER2-negative advanced breast cancer, where mutations in the ESR1 gene cause treatment resistance.
- Scientists used blood tests to detect circulating tumour DNA early, allowing therapy switches before cancer growth, improving patient outcomes significantly.
- Camizestrant extended the time patients lived without their cancer worsening or dying by 56%, with a median duration of 16 months compared to 9 months for standard treatments.
- These findings represent a pivotal advance in personalized breast cancer care, potentially delaying chemotherapy and improving precision treatment strategies globally.
Insights by Ground AI
Does this summary seem wrong?
17 Articles
17 Articles
All
Left
4
Center
7
Right
Blood test-guided treatment with AstraZeneca pill cuts breast cancer progression risk
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts said on Sunday.
·United Kingdom
Read Full Article
Coverage Details
Total News Sources17
Leaning Left4Leaning Right0Center7Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 36%
C 64%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
